ERBB2 and neoplasm: ES2B-C001, a VLP-based vaccine being developed for human breast cancer therapy, displayed strong immunogenicity and powerful anti-tumor and anti-metastatic activities in preclinical mouse models of HER-2+ mammary carcinoma.